DelveInsight’s ‘Hereditary Angioedema Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and Hereditary Angioedema Pipeline therapies in various stages of Hereditary Angioedema clinical trial development, major pharmaceutical Hereditary Angioedema Companies are working to advance the Hereditary Angioedema pipeline space and future growth potential of the Hereditary Angioedema pipeline domain.
For Hereditary Angioedema emerging drugs, the Hereditary Angioedema pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and Mechanism of Action. The Hereditary Angioedema pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key takeaways of the Hereditary Angioedema Pipeline Report
- Over 20+ Hereditary Angioedema companies are evaluating 30+ Hereditary Angioedema pipeline therapies in various stages of development, and their anticipated acceptance in the Hereditary Angioedema market would significantly increase market revenue.
- The leading Hereditary Angioedema Companies are working to develop drug candidates to improve Hereditary Angioedema treatment landscape include BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals Inc., Intellia Therapeutics, and others.
- Promising Hereditary Angioedema Pipeline Therapies include CINRYZE with rHuPH20, Icatibant, Donidalorsen, TAK-743 300 mg, CSL312, and others.
- The Hereditary Angioedema Companies and academics are working to assess challenges and seek opportunities that could influence Hereditary Angioedema R&D. The Hereditary Angioedema pipeline therapies under development are focused on novel approaches to treat/improve Hereditary Angioedema.
Request a sample and discover the recent breakthroughs happening in Hereditary Angioedema pipeline landscape @ Hereditary Angioedema Pipeline Outlook Report
Hereditary Angioedema Overview
Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting. Swelling in the airway can restrict breathing and lead to life-threatening obstruction of the airway. About one-third of people with this condition develop a non-itchy rash called erythema marginatum during an attack.Symptoms of hereditary angioedema typically begin in childhood and worsen during puberty. On average, untreated individuals have an attack every 1 to 2 weeks, and most episodes last for about 3 to 4 days. The frequency and duration of attacks vary greatly among people with hereditary angioedema, even among people in the same family.
Hereditary Angioedema Emerging Drugs Profile
- KVD900: KalVista Pharmaceuticals
KVD900 is a candidate from our oral portfolio of plasma kallikrein inhibitors. It exhibits high solubility and high permeability and is uniquely suited for on-demand treatment of HAE attacks, with rapid uptake into the plasma and high plasma concentrations. Data in phase II clinical trial for KVD900 is anticipated in the fourth quarter of 2020.Currently the drug is in Phase III stage of development for the treatment of Hereditary angioedema.
- PHA121: Pharvaris
PHA121 is a novel small molecule with drug-like properties. In preclinical studies, PHA121 demonstrates highly potent and selective competitive antagonism of the B2 receptor, and shows rapid and potent activity on oral dosing in a bradykinin-mediated disease model. It is currently in phase II stage of development.
- BMN 331: BioMarin Pharmaceutical
BMN 331 is a gene therapy product candidate for HAE. It is currently in Phase I stage of development.
Find out more about the Hereditary Angioedema Diagnosis and Treatment of patients @ Hereditary Angioedema Ongoing Clinical Trials Analysis
Hereditary Angioedema Key Companies and Pipeline Therapies
- Takeda: Takhzyro
- Shire/Takeda: Firazyr
- CSL Behring: Cinryze
- Pharming Group: Kalbitor
- BioCryst Pharmaceuticals: Haegarda
- Ionis Pharmaceuticals: Berinert
- KalVista Pharmaceuticals: Ruconest
Hereditary Angioedema Pipeline Therapeutics Assessment
Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
Discover more about the list of FDA-approved drugs for Hereditary Angioedema @ Hereditary Angioedema Treatment Landscape
Scope of the Hereditary Angioedema Pipeline Report
- Coverage- Global
- Hereditary Angioedema Companies- BioCryst Pharmaceuticals (NYSE: BCRX), KalVista Pharmaceuticals (NYSE: KALV), Pharvaris (NYSE: PHVS), BioMarin Pharmaceutical (NYSE: BMRN), Ionis Pharmaceuticals Inc (NYSE: IONS), Intellia Therapeutics (NYSE: NTLA), and others.
- Hereditary Angioedema Pipeline Therapies- CINRYZE with rHuPH20, Icatibant, Donidalorsen, TAK-743 300 mg, CSL312, and others.
- Hereditary Angioedema Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type
Dive deep into rich insights for Hereditary Angioedema Emerging Therapies and Ongoing Clinical Trials; visit @ Hereditary Angioedema Emerging Therapies and Companies
Table of Content
- Introduction
- Hereditary angioedema Executive Summary
- Hereditary angioedema: Overview
- Hereditary angioedema Pipeline Therapeutics
- Hereditary angioedema Therapeutic Assessment
- Hereditary angioedema – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Hereditary angioedema Collaboration Deals
- Late Stage Products (Phase III and NDA)
- KVD900: KalVista Pharmaceuticals
- Mid Stage Products (Phase II)
- PHA121: Pharvaris
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- BMN 331: BioMarin Pharmaceutical
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Drug Name: Company Name
- Inactive Products
- Hereditary angioedema Key Companies
- Hereditary angioedema Key Products
- Hereditary angioedema- Unmet Needs
- Hereditary angioedema- Market Drivers and Barriers
- Hereditary angioedema- Future Perspectives and Conclusion
- Hereditary angioedema Analyst Views
- Hereditary angioedema Key Companies
- Appendix
For further information on the Hereditary angioedema Pipeline therapeutics, reach out @ Hereditary angioedema Market Drivers and Barriers
Latest Pharmaceuticals Market Research Reports 2023 by DelveInsight
CAR-T Pipeline | Stem Cell Market | Anastomotic Leak Devices Market | Blastomycosis Market | Oncolytic Virus Cancer Therapy Pipeline | Superficial Punctate Keratitis | Persistent Epithelial Defect Market | Ranibizumab Biosimilars Insight | Brucellosis Market
Latest Blogs by DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com